Molecular mode of action of NKP-1339 – a clinically investigated ruthenium-based drug – involves ER- and ROS-related effects in colon carcinoma cell lines
Tóm tắt
Sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] (NKP-1339) is a clinically investigated ruthenium-based metal complex, which shows promising results in solid tumors, such as non-small cell lung cancer, colorectal carcinoma, and most distinctively in gastrointestinal neuroendocrine tumors. In previous studies, fast binding to albumin as well as transferrin could be shown. The enhanced permeability and retention (EPR) effect, which is diversely being exploited for tumor targeting, could therefore be applicable for NKP-1339. Here we studied the serum dependence of its biological activity in various methods, influencing its cellular accumulation, cytotoxicity as well as the generation of reactive oxygen species (ROS). ROS lead to Nrf2 activation, which is known to activate antioxidant response gene transcription. GRP78 down-regulation on the protein level suggests ER associated protein degradation (ERAD) as a mode of action, as RNA levels are only mildly affected. Another important part for the mode of action is endoplasmic reticulum (ER) stress, as different factors are highly upregulated on the protein level. For example PERK, a transmembrane receptor which is released by GRP78 when the ER is disturbed, is upregulated and phosphorylated. EIF2α is phosphorylated, which leads to an inhibition of CAP-dependent translation and other stress responses. The transcription factor CHOP (DDIT3), which promotes ER stress dependent apoptosis, is time and concentration dependently upregulated. Finally cytotoxicity tests could prove that inhibition of ER stress and ER stress-mediated apoptosis leads to decreased cytotoxic effects of NKP-1339, which highlights the involvement of this mechanism in the mode of action.
Tài liệu tham khảo
Bruijnincx PC, Sadler PJ (2008) New trends for metal complexes with anticancer activity. Curr Opin Chem Biol 12:197–206
Timerbaev AR, Hartinger CG, Aleksenko SS, Keppler BK (2006) Interactions of antitumour metallodrugs with serum proteins: advances in characterisation using modern analytical methodology. Chem Rev 106:2224–2248
Kratz F, Keppler BK, Hartmann M, Messori L, Berger MR (1996) Comparison of the antiproliferative activity of two antitumour ruthenium(III) complexes with their apotransferrin and transferrin-bound forms. Metal-Based Drugs 3:15–23
Sulyok M, Hann S, Hartinger CG, Keppler BK, Stingeder G, Koellensperger G (2005) Two dimensional separation schemes for investigation of the interaction of an anticancer ruthenium(III) compound with plasma proteins. J Anal At Spectrom 20:856–863
Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65:271–284
Heffeter P, Pongratz M, Steiner E, Chiba P, Jakupec MA, Elbling L, Marian B, Körner W, Sevelda F, Micksche M, Keppler BK, Berger W (2005) Intrinsic and acquired forms of resistance against the anticancer ruthenium compound KP1019 [indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (FFC14A). J Pharmacol Exp Ther 312:281–289
Thompson DS, Weiss GJ, Jones SF, Burris HA, Ramanathan RK, Infante JR, Bendell JC, Ogden A, Von Hoff DD (2012) NKP-1339: Maximum tolerated dose defined for first-in-human GRP78 targeted agent. J Clin Oncol 30(Suppl): abstract #3033
Healy SJM, Gorman AM, Mousavi-Shafaei P, Gupta S, Samali A (2009) Targeting the endoplasmic reticulum-stress response as an anticancer strategy. Eur J Pharmacol 625:234–246
Szegezdi E, Logue SE, Gorman AM, Samali A (2006) Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep 7:880–885
Farooqi AA, Li KT, Fayyaz S, Chang YT, Ismail M, Liaw CC, Yuan SSF, Tang JY, Chang HW (2015) Anticancer drugs for the modulation of endoplasmic reticulum stress and oxidative stress. Tumour Biol 36:5743–5752
Van Huizen R, Martindale JL, Gorospe M, Holbrook NJ (2003) P58IPK, a novel endoplasmic reticulum stress-inducible protein and potential negative regulator of eIF2α signaling. J Biol Chem 278:15558–15564
Peti W, Pieper T, Sommer M, Keppler BK, Giester G (1999) Synthesis of tumor-inhibiting complex salts containing the anion trans-tetrachlorobis(indazole)ruthenate(III) and crystal structure of the tetraphenylphosphonium salt. Eur J Inorg Chem 1999:1551–1555
Filak LK, Göschl S, Heffeter P, Ghannadzadeh Samper K, Egger AE, Jakupec MA, Keppler BK, Berger W, Arion VB (2013) Metal-arene complexes with indolo[3,2-c]-quinolines: effects of ruthenium vs osmium and modifications of the lactam unit on intermolecular interactions, anticancer activity, cell cycle, and cellular accumulation. Organometallics 32:903–914
Bozaykut P, Ozer NK, Karademir B (2014) Regulation of protein turnover by heat shock proteins. Free Radic Biol Med 77:195–209
Fujita E, Kouroku Y, Isoai A, Kumagai H, Misutani A, Matsuda C, Hayashi YK, Momoi T (2007) Two endoplasmic reticulum-associated degradation (ERAD) systems for the novel variant of the mutant dysferlin: ubiquitin/proteasome ERAD(I) and autophagy/lysosome ERAD(II). Hum Mol Gen 16:618–629
Dömötör O, Hartinger CG, Bytzek AK, Kiss T, Keppler BK, Enyedy EA (2013) Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies. J Biol Inorg Chem 18:9–17
Ghuman J, Zunszain PA, Petitpas I, Bhattacharya AA, Otagiri M, Curry S (2005) Structural basis of the drug-binding specificity of human serum albumin. J Mol Biol 353:38–52
Kratz F (2014) A clinical update of using albumin as a drug vehicle - a commentary. J Control Release 190:331–336
Webb MI, Wu B, Jang T, Chard RA, Wong EWY, Wong MQ, Yapp DTT, Walsby CJ (2013) Increasing the bioavailability of RuIII anticancer complexes through hydrophobic albumin interactions. Chem Eur J 19(50):17031–17042
Bergamo A, Messori L, Piccioli F, Cocchietto M, Sava G (2003) Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin. Invest New Drugs 21:401–411
Novohradský V, Bergamo A, Cocchietto M, Zajac J, Brabec V, Mestroni G, Sava G (2015) Influence of the binding of reduced NAMI-A to human serum albumin on the pharmacokinetics and biological activity. Dalton Trans 44(4):1905–1913
Kapitza S, Jakupec MA, Uhl M, Keppler BK, Marian B (2005) The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells. Cancer Lett 226:115–121
Lee AS (2007) GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res 67:3496–3499